ライフサイエンスコーパス: depressive disorder

1 scale (range, 0-60; >=16 indicates possible depressive disorder).

2 2 (PHQ-2; range, 0-6; >=3 indicates possible depressive disorder).

3 r for ACS in combination with a diagnosis of depressive disorder.

4 S to real RNA-Seq data from a study of major depressive disorder.

5 No significant difference was found in major depressive disorder.

6 aluated oral NSI-189 as monotherapy in major depressive disorder.

7 in a clinical setting in patients with major depressive disorder.

8 ngly with recurrent and single-episode major depressive disorder.

9 d with other mental disorders, such as major depressive disorder.

10 to affect-related illnesses, including major depressive disorder.

11 are also implicated in the etiology of major depressive disorder.

12 marker of inflammation associated with major depressive disorder.

13 administration in treatment-resistant major depressive disorder.

14 ve in bipolar disorder but negative in major depressive disorder.

15 in particular for treatment-resistant major depressive disorder.

16 els lower than the threshold indicative of a depressive disorder.

17 has a closer genetic association with major depressive disorder.

18 biomarker of stress vulnerability and major depressive disorder.

19 d with psychiatric disorders including major depressive disorder.

20 tidepressant approved for treatment of major depressive disorder.

21 trial of sertraline versus placebo for major depressive disorder.

22 is in development for the treatment of major depressive disorder.

23 ding posttraumatic stress disorder and major depressive disorder.

24 e in neuroticism, psychological distress, or depressive disorder.

25 to BDNF expression is associated with major depressive disorder.

26 lammation pathways in the treatment of major depressive disorder.

27 of stress-related disorders, including major depressive disorder.

28 rget the underlying pathophysiology of major depressive disorder.

29 eatment-seeking adult outpatients with major depressive disorder.

30 s in women not formally diagnosed with major depressive disorder.

31 s an effective add-on intervention for major depressive disorder.

32 these interventions for prevention of major depressive disorder.

33 ior studies indicate is hyperactive in major depressive disorder.

34 anging from 9,529 with autism to 88,182 with depressive disorder.

35 re a particularly disabling feature of major depressive disorder.

36 order is more strongly correlated with major depressive disorder.

37 icipants consisted of adults with persistent depressive disorder.

38 trimental effect of BMI on the risk of major depressive disorder.

39 sants are similar in BD as in unipolar major depressive disorder.

40 l cortex (mPFC) has been implicated in major depressive disorder.

41 cores for behavioral disinhibition and major depressive disorder.

42 t stress, modeling multiple aspects of major depressive disorder.

43 able response for a drug treatment for major depressive disorder.

44 ively representing 2,928 patients with major depressive disorder.

45 otherapy practice, CBT, in adults with major depressive disorder.

46 n between the Netrin-1/DCC pathway and major depressive disorder.

47 nisms of maladaptive learning in anxiety and depressive disorders.

48 edisposes individuals to develop anxiety and depressive disorders.

49 ed genetic variants of SIRT1 linked to major depressive disorders.

50 sian BD multiplex families (166 BD, 78 major depressive disorder, 151 unaffected) as well as 438 subj

51 visit were anxiety disorders (20.0%), major depressive disorder (16.9%), and substance use disorders

52 0.05 for other income quintiles), those with depressive disorders (28.78 [20.04-41.33]; p<0.0001) and

53 ttempters and 8,786 nonattempters with major depressive disorder; 3,264 attempters and 5,500 nonattem

54 ntrol, and conduct disorders; 11% (9-13) for depressive disorders; 9% (7-10) for obsessive-compulsive

55 r schizophrenia, alcohol use disorder, major depressive disorder, a combined bipolar disorder-schizop

56 tic resonance imaging in patients with major depressive disorder, a disease associated with an altere

57 In patients with major depressive disorder, a dysfunctional reward-system may e

58 s is a primary objective when treating major depressive disorder-a disease that afflicts ~20% of the

59 sorder and comorbid conditions such as major depressive disorder and alcohol use disorder.

60 d to pathological circuitry, including major depressive disorder and Alzheimer disease.

61 The search terms included cytokine, depressive disorder and antidepressant and their synonym

62 ter puberty, females are more prone to major depressive disorder and anxiety disorders compared to ma

63 der, along with the increased rates of major depressive disorder and anxiety disorders in one or more

64 the shared molecular genetic basis of major depressive disorder and bipolar disorder and to highligh

65 c associations, and genetic studies of major depressive disorder and bipolar disorder can be combined

66 Analyzing subtypes of major depressive disorder and bipolar disorder provides eviden

67 Mood disorders (including major depressive disorder and bipolar disorder) affect 10% to

68 enetic association with schizophrenia, major depressive disorder and bipolar disorder.

69 were compared with those of women with major depressive disorder and chronic widespread pain (MD-P) a

70 R to real RNA-Seq data from a study of major depressive disorder and discuss STIR's straightforward e

71 s of brain anatomy between people with major depressive disorder and healthy control subjects, but fe

72 % confidence interval = 1.04-1.23), and both depressive disorder and high severity predicted higher I

73 Synergistic effects of depressive disorder and NR3C1 hypermethylation on long-t

74 in disorders (including, among others, major depressive disorder and obsessive-compulsive disorder, a

75 ed neuropsychiatric disorders, such as major depressive disorder and posttraumatic stress disorder, e

76 ere collected for 28 patients (20 with major depressive disorder and seven with bipolar II disorder;

77 ct, the bidirectional relation between major depressive disorder and sleep has been well-documented.

78 e durability and safety of SAGE-217 in major depressive disorder and to compare SAGE-217 with availab

79 vidence to suggest that cannabinoids improve depressive disorders and symptoms, anxiety disorders, at

80 tional disorders, including addiction, major depressive disorder, and autism (Cousins et al., 2002; K

81 motional face processing, diagnosis of major depressive disorder, and greater self-reported depressio

82 citatory neurotransmission occurs with major depressive disorder, and may be normalized by antidepres

83 with schizophrenia, bipolar disorder, major depressive disorder, and obsessive-compulsive disorder.

84 m spectrum disorder, bipolar disorder, major depressive disorder, and schizophrenia.

85 m spectrum disorder, bipolar disorder, major depressive disorder, and schizophrenia.

86 ion, FMRP targets were associated with major depressive disorder, and we present novel evidence of as

87 ing enhancing memory and learning, reversing depressive disorders, and modulating cognitive functions

88 In sibling analyses, we found that men with depressive disorder, anxiety disorder, alcohol use disor

89 n-6 (IL-6) and C-reactive protein with major depressive disorder are well established, evidence for l

90 perationalize depression severity, and major depressive disorder as defined in the Diagnostic and Sta

91 morphometry studies in schizophrenia, major depressive disorder, bipolar disorder, addiction, and an

92 mpt, using cohorts of individuals with major depressive disorder, bipolar disorder, and schizophrenia

93 rge genetic studies of six phenotypes: major depressive disorder, bipolar disorder, attention-deficit

94 Brain structural abnormalities in major depressive disorder, bipolar disorder, schizophrenia, an

95 rimary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, ob

96 hest deletion burdens were observed in major depressive disorder brain, at levels greater than Kearns

97 t-line antidepressants for adults with major depressive disorder, but success is limited and patients

98 icrobiota dysbiosis has been linked to major depressive disorder, but the mechanisms whereby the micr

99 nd bipolar disorder, and an additional major depressive disorder cohort from UK Biobank (total: 185,2

100 Comparison with a matched major depressive disorder cohort revealed significant divergen

101 Patients with major depressive disorder completed two rtfMRI-nf sessions (18

102 ders (schizophrenia, bipolar disorder, major depressive disorder, cross disorder, attention-deficit/h

103 c correlation was found between PD and major depressive disorder, depressive symptoms, and neuroticis

104 tic risk for behavioral disinhibition, major depressive disorder, depressive symptoms, autism spectru

105 profiles of individuals with PTSD and major depressive disorder despite their high comorbidity.

106 al design, 36 patients with first onset of a depressive disorder (Diagnostic and Statistical Manual o

107 Almost two-thirds of patients with major depressive disorder do not achieve remission with initia

108 no therapy did not reduce episodes of major depressive disorder during 1 year.

109 tal depression, which is the occurrence of a depressive disorder during pregnancy or following childb

110 Major depressive disorder emerges from the complex interaction

111 Patients with current major depressive disorder exhibited increased fecal interleuki

112 Adults with major depressive disorder frequently do not achieve remission

113 types analysed in UK Biobank only were major depressive disorder, generalised anxiety disorder, bipol

114 atients who had a primary diagnosis of major depressive disorder, had a score >=18 on the 17-item Ham

115 icacy of dopamine agonists in treating major depressive disorder has been hypothesized to stem from e

116 Imaging studies of major depressive disorder have reported structural and functio

117 a higher likelihood of remission from major depressive disorder in children undergoing PCIT-ED (B =

118 rt study of 53,034 patients diagnosed with a depressive disorder in fiscal year 2017 in the U.S. Vete

119 r development as a novel treatment for major depressive disorder in humans.

120 a higher likelihood of remission from major depressive disorder in the PCIT-ED group (B = 0.14; SE =

121 Adults with newly diagnosed major depressive disorder in the United States.

122 s that CRY1Delta11 was associated with major depressive disorder, insomnia, and anxiety.

123 dication-free 18- to 65-year-olds with major depressive disorder, insomnia, and suicidal ideation.

124 Major depressive disorder is a common mental health condition

125 Major depressive disorder is a common mood disorder in the eld

126 Major depressive disorder is a common psychiatric disorder ass

127 Major depressive disorder is a leading cause of disability and

128 Major depressive disorder is a remarkably common and often sev

129 Major depressive disorder is a result of the complex interplay

130 Major depressive disorder is a significant and costly cause of

131 One of the core symptoms of major depressive disorder is anhedonia, an inability to experi

132 Major depressive disorder is associated with aberrant resting-

133 Major depressive disorder is heritable and a leading cause of

134 ffective and safe for the treatment of major depressive disorder is unknown.

135 microtubule modifications in progression of depressive disorders is emerging.

136 ics, the biological characteristics of major depressive disorder may be close to those of HCS.

137 Seventy eight adolescents with major depressive disorder (MDD) (age mean [SD] = 14.9 +/- 1.5,

138 We compare participants diagnosed with Major Depressive Disorder (MDD) (n = 64) to healthy controls (

139 Recurrent and chronic major depressive disorder (MDD) accounts for a substantial par

140 alance in 35 unmedicated subjects with major depressive disorder (MDD) and 25 healthy controls enroll

141 Major depressive disorder (MDD) and Alzheimer's disease (AD) r

142 Major depressive disorder (MDD) and generalized anxiety disord

143 Major depressive disorder (MDD) and loneliness are phenotypica

144 contribute to symptoms associated with major depressive disorder (MDD) and post-traumatic stress diso

145 (LC omega-3 PUFA) have been linked to major depressive disorder (MDD) and preterm birth (PTB), and p

146 The UK Biobank concurrently assessed Major Depressive Disorder (MDD) and self-reported lifetime exp

147 Early life adversity (ELA) increases major depressive disorder (MDD) and suicide risk and potential

148 enia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD) are heritable psychiatric diso

149 Medications to treat major depressive disorder (MDD) are not equally effective acro

150 pressed in the brain, in subjects with major depressive disorder (MDD) as compared with age- and sex-

151 nvestigate the changes of olfaction of major depressive disorder (MDD) before and after medical treat

152 vulsive therapy (ECT) is effective for major depressive disorder (MDD) but its effects on memory limi

153 V) and HCMV has never been examined in major depressive disorder (MDD) despite the presence of inflam

154 nome-wide association analyses between major depressive disorder (MDD) genetic risk score (GRS) and 9

155 Major depressive disorder (MDD) has an enormous impact on glob

156 The neurophysiology of major depressive disorder (MDD) has become a particular focus

157 ontotemporal cortices of patients with major depressive disorder (MDD) has been demonstrated using fu

158 Subcortical volumetric changes in major depressive disorder (MDD) have been purported to underli

159 Major depressive disorder (MDD) in children and adolescents is

160 nal interventions on the prevention of major depressive disorder (MDD) in overweight adults are unkno

161 Major depressive disorder (MDD) in the elderly is a risk facto

162 Major depressive disorder (MDD) is a complex condition with un

163 Major depressive disorder (MDD) is a leading cause of disabili

164 More severe anhedonia in major depressive disorder (MDD) is a negative predictor of ant

165 Major depressive disorder (MDD) is a serious mental illness, c

166 Major depressive disorder (MDD) is a serious, heterogeneous di

167 Major depressive disorder (MDD) is associated with alterations

168 Although major depressive disorder (MDD) is associated with altered fun

169 Major depressive disorder (MDD) is associated with altered glo

170 Major depressive disorder (MDD) is associated with an increase

171 ct treatment response in patients with major depressive disorder (MDD) is challenging, in part becaus

172 Neuroimaging studies have shown that major depressive disorder (MDD) is characterized by abnormal n

173 tinguishing bipolar disorder (BD) from major depressive disorder (MDD) is clinically challenging, esp

174 r knowledge of the biological basis of major depressive disorder (MDD) is derived from studies of chr

175 Although major depressive disorder (MDD) is highly prevalent, its patho

176 Major depressive disorder (MDD) is moderately heritable, with

177 Patients with major depressive disorder (MDD) often have structural and func

178 t-traumatic stress disorder (PTSD) and major depressive disorder (MDD) on the basis of robust and dis

179 wever, the proportion of never-treated major depressive disorder (MDD) patients who exhibit inflammat

180 ata of 130 individuals (65 melancholic major depressive disorder (MDD) patients, 65 healthy controls)

181 tance observed in approximately 30% of major depressive disorder (MDD) patients.

182 itors (SSRIs) are standard of care for major depressive disorder (MDD) pharmacotherapy, but only appr

183 Patients with major depressive disorder (MDD) present with heterogeneous sym

184 me-wide association studies (MWAS) for major depressive disorder (MDD) to identify sites of potential

185 enetic data (n = 3907) from the ENIGMA Major Depressive Disorder (MDD) working group.

186 udy participants were 27 subjects with major depressive disorder (MDD), 29 subjects with bipolar diso

187 ssant partial- and non-responders with major depressive disorder (MDD), a systematic search of Pubmed

188 ondition (ASC), bipolar disorder (BD), major depressive disorder (MDD), and schizophrenia (SCZ; n = 2

189 fferences in kynurenine metabolites in major depressive disorder (MDD), bipolar disorder (BD), and sc

190 f major psychiatric disorders, such as major depressive disorder (MDD), bipolar disorder (BD), and sc

191 s identified genetic correlations with Major Depressive Disorder (MDD), Bipolar Disorder (BD), Schizo

192 a-GWASs of self-reported and recurrent major depressive disorder (MDD), bipolar disorder and schizoph

193 ical thickness have been identified in major depressive disorder (MDD), but findings have been variab

194 otonergic dysfunction is implicated in major depressive disorder (MDD), but the mechanisms of this re

195 ansmission has long been implicated in major depressive disorder (MDD), for which selective serotonin

196 n neuropsychiatric diseases, including major depressive disorder (MDD), has been postulated.

197 ings in stress disorders, particularly major depressive disorder (MDD), highlighting insights from po

198 e adversity (ELA) is a risk factor for major depressive disorder (MDD), however the underlying mechan

199 in psychiatric diseases, particularly major depressive disorder (MDD), remains largely unknown.

200 The etiology of major depressive disorder (MDD), the leading cause of worldwid

201 S-ketamine (esketamine) nasal spray in major depressive disorder (MDD), we performed a genome-wide as

202 Using RNA-Seq data from a study of major depressive disorder (MDD), we show that NPDR with covari

203 al excitatory to inhibitory balance in major depressive disorder (MDD), which afflicts ~14%-20% of in

204 adjunctive treatment of patients with major depressive disorder (MDD), who did not respond adequatel

205 leviation and quality of life (QoL) in major depressive disorder (MDD).

206 mmune processes in the pathogenesis of major depressive disorder (MDD).

207 eat stress (CSDS) and in patients with major depressive disorder (MDD).

208 tion contribute to the pathogenesis of major depressive disorder (MDD).

209 s ability to identify individuals with major depressive disorder (MDD).

210 suicidal ideation (SI) in adults with major depressive disorder (MDD).

211 modulator for adjunctive treatment of major depressive disorder (MDD).

212 study resting-state brain activity in major depressive disorder (MDD).

213 health and is strongly associated with major depressive disorder (MDD).

214 schizophrenia (SCZ), and unchanged in major depressive disorder (MDD).

215 ges in brain and blood associated with major depressive disorder (MDD).

216 n several brain areas of subjects with major depressive disorder (MDD).

217 A receptor (5-HT1AR) are implicated in major depressive disorder (MDD).

218 n implicated in the pathophysiology of major depressive disorder (MDD).

219 etiology of mood disorders, including major depressive disorder (MDD).

220 ciated psychiatric diseases, including major depressive disorder (MDD).

221 h subcortical anatomy in patients with major depressive disorder (MDD).

222 with comorbid mood disorders including major depressive disorder (MDD).

223 iated disorders later in life, such as major depressive disorder (MDD).

224 ell-documented neural abnormalities in major depressive disorder (MDD).

225 ted finding in neuroimaging studies of major depressive disorder (MDD).

226 ory pathways and the gut microbiome in major depressive disorder (MDD).

227 s) may be efficacious for treatment of major depressive disorder (MDD).

228 increased in a subset of patients with major depressive disorder (MDD).

229 or treatment outcomes in patients with major depressive disorder (MDD).

230 ic plasticity is often associated with major depressive disorder (MDD).

231 pha) treatment for Hepatitis-C develop major depressive disorder (MDD).

232 ntidepressant effects in patients with major depressive disorder (MDD).

233 onse has been a clinical challenge for major depressive disorder (MDD).

234 renia (SZ), bipolar disorder (BD), and major depressive disorder (MDD).

235 TMS) is a commonly- used treatment for major depressive disorder (MDD).

236 nimal phenotyping and strictly defined major depressive disorder (MDD): the former has a lower genoty

237 tor antagonist, ketamine, for treating major depressive disorder (MDD); however, its neural mechanism

238 Endothelial dysfunction is evident in major depressive disorder (MDD); however, the molecular mediat

239 (MS, 4,888 cases and 10,395 controls), major depressive disorder (MDD, 1,475 cases and 2,144 controls

240 n models, PSs indexing 6 risk factors (major depressive disorder [MDD], attention deficit/hyperactivi

241 We analyzed data from outpatients with major depressive disorder (n = 124) randomized to receive esci

242 Individuals with major depressive disorder (n = 26) and healthy controls (n = 2

243 autism spectrum disorder (N = 126), or major depressive disorder (N = 398; total N = 2937 from 12 sit

244 We recruited unmedicated patients with major depressive disorder (N = 71 approached; N = 39 randomise

245 a diagnosis of major depressive disorder or depressive disorder not otherwise specified and no prior

246 ere made from 2007 to 2012, including DSM-IV depressive disorder, NR3C1 methylation, and various demo

247 ible novel treatment for diseases like major depressive disorder, obesity, chronic pain, and certain

248 ant enrichments of the heritability of major depressive disorder, obsessive-compulsive disorder and s

249 ribute to the heritability of anxiety, major depressive disorder, obsessive-compulsive disorder, schi

250 ly in clinical trials for treatment of major depressive disorder, offers the opportunity for the deve

251 ntrols and from patients with remitted major depressive disorder on antidepressants.

252 one associated with suicide attempt in major depressive disorder, one associated with suicide attempt

253 67,807 individuals with a diagnosis of major depressive disorder or depressive disorder not otherwise

254 about the role(s) of these neurons in major depressive disorder or in mediating the delayed behavior

255 insically linked to the development of major depressive disorder, originate in part from the dysregul

256 nnectivity at 1-week post treatment in major depressive disorder patients randomized to 8 weeks of se

257 lso observed in human fibroblasts from major depressive disorder patients.

258 markers in human NAc from nonmedicated major depressive disorder patients.

259 Applying the major depressive disorder polygenic risk score (MDD-PRS) deriv

260 ession, and many prominent theories of major depressive disorder propose a role for abnormal cortico-

261 tly associated with suicide attempt in major depressive disorder (R(2)=0.25%), bipolar disorder (R(2)

262 negatively genetically correlated with major depressive disorder (r(g)=-0.24) and ADHD (r(g)=-0.10).

263 elated with schizophrenia (r(g)=0.22), major depressive disorder (r(g)=0.26), and attention deficit h

264 Most guidelines for major depressive disorder recommend initial treatment with eit

265 Effective pharmacotherapy for major depressive disorder remains a major challenge, as more t

266 nment interaction hypotheses regarding major depressive disorder remains strong despite controversy s

267 ), bipolar disorder (BD) and recurrent major depressive disorder (rMDD) are common psychiatric illnes

268 al treatment for severe and refractory major depressive disorder since 2005.

269 oactivity and right parietal hypoactivity in depressive disorders, so aspects of lateralized anatomy

270 associated with a greater reduction in major depressive disorder symptoms (r = -.12, p > .4).

271 associated with a greater reduction in major depressive disorder symptoms (r = -.24, p = .05).

272 lity is an important symptom domain of major depressive disorder that is not fully reflected in depre

273 arched for all case-control studies on major depressive disorder that reported microarray or RNA sequ

274 sing real RNA-seq data from a study of major depressive disorder.The cnCV method has similar training

275 samples of SSRI-treated patients with major depressive disorder: the MARS (n = 253, P = 0.0169) and

276 at Pdcd4 might be a new potential target for depressive disorder therapy.

277 icting the response of 894 adults with major depressive disorder to cognitive behavior therapy.

278 high risk for transition from a diagnosis of depressive disorder to one of bipolar disorder.

279 outpatients with epilepsy and current major depressive disorder to sertraline or weekly CBT for 16 w

280 Major depressive disorder topped ischemic heart disease as the

281 3 individuals with treatment-resistant major depressive disorder (TRD) and 25 healthy volunteers (HVs

282 e FDA for treating treatment-resistant major depressive disorder (TRD) in 2019, almost 50 years after

283 A total of 116 participants with major depressive disorder treated with sertraline in stage 1 s

284 f 41 subjects with treatment-resistant major depressive disorder underwent one [(18)F]FEPPA positron

285 cross-sectional association between current depressive disorder (vs.

286 studies linking transcriptional profiles to depressive disorder, we examined whether post-endotoxin

287 sing independent microarray studies of major depressive disorder, we find that including prior knowle

288 In treating major depressive disorder, we lack tests anchored in neurobiol

289 al of Mental Disorders IV criteria for major depressive disorder were eligible and consented to take

290 Genes abnormally expressed in major depressive disorder were enriched for innate immune-rela

291 een schizophrenia/bipolar disorder and major depressive disorder were found in the limbic system, whi

292 METHOD: Adult outpatients with major depressive disorder were randomly assigned to open or pl

293 -type potassium channel-for the treatment of depressive disorders, which may exert a therapeutic effe

294 xpression are associated with risk for major depressive disorder while those of higher expression are

295 ge 2 sample comprised 87 patients with major depressive disorder who switched medication and 38 healt

296 Major depressive disorder with psychotic features (psychotic d

297 erm prognosis of ACS only in the presence of depressive disorder with significant synergistic interac

298 om the Psychiatric Genomics Consortium Major Depressive Disorder Working Group and the UK Biobank.

299 an effective treatment for refractory major depressive disorder, yet no studies have characterized t

300 Lithium has been used to treat major depressive disorder, yet the neural circuit mechanisms u